00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
23:41 , May 1, 2019 |  BC Innovations  |  Translation in Brief

White matter matters in Alzheimer’s

An MIT team has identified Alzheimer’s disease-associated changes in gene expression that vary based on cell type, including myelin-related genes, suggesting new pathways that can be explored to treat the disease. Described in a Nature...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
19:47 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
22:40 , Dec 19, 2018 |  BC Extra  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
00:19 , Jun 24, 2016 |  BC Extra  |  Financial News

Annexon raises $44M in B round

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $44 million in a series B round led by new investor New Enterprise Associates. New investor Correlation Ventures also participated, as did existing investors including Novartis Venture...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Complement 3 (C3); complement component 1 q subcomponent (C1q); complement component 1 q subcomponent A chain (C1QA)

Neurology INDICATION: Alzheimer's disease (AD) Studies in mice suggest inhibiting C3, the C3-activator C1q , or the C1q subunit C1QA could help treat AD. Hippocampal and cortical levels of C1q were higher in two transgenic...
07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...